Elanco Animal Health Incorporated (ELAN)

NYSE: ELAN · USD

$22.6

-0.02 (-0.1%)· Recorded snapshot

Market cap	11.3B
Revenue (ttm)	5B
Net income (ttm)	-199M
EPS (ttm)	-$0.41
Shares out	499.6M
P/E (forward)	19.2x
Volume	2,995,977
Beta	1.71

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 5B
Net income (ttm): -199M
EPS (ttm): -$0.41
P/E (forward): 19.2x
Market cap: 11.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E19.2

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-3

P25 n/aP50 n/aP75 n/a

ROIC3.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ELAN indicators

Market & fundamental data

Available fields

244

Groups with data

Currency

USD

Showing 244 of 244 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001739104
Company name	Elanco Animal Health Incorporated
Country	United States
Country code	US
CUSIP number	28414H103
Earnings date	2026-11-06
Earnings time	bmo
Employees	9,900
Employees change	450
Employees growth	4.76%
Enterprise value	$15B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1954
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2018-09-20
Is primary listing	Yes
Is SPAC	No
ISIN number	US28414H1032
Last 10-K release date	2026-02-24
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$11.3B
Market cap category	Large-Cap
Next earnings date	2026-11-06
Options	Yes
Price	$22.64
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ELAN
U.S. state	Indiana
Website	https://www.elanco.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	21.35x
Earnings yield	-1.79%
EV/EBIT	44.12x
EV/EBITDA	14.9x
EV/FCF	39.58x
EV/Sales	2.99x
FCF / EV yield	2.53%
FCF yield	3.36%
Forward EV/Sales	2.85x
Forward P/E	19.21x
Forward P/S	2.14x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	37.04x
P/(OCF - SBC) ratio	20.8x
P/B ratio	1.72x
P/FCF ratio	29.81x
P/OCF ratio	18.31x
P/S ratio	2.25x
PEG ratio	1.74x
Price/EBITDA ratio	11.22x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	6.77%
EBITDA margin	20.06%
FCF margin	7.55%
Gross margin	55.36%
Operating margin	6.77%
Pretax margin	-3.31%
Profit margin	-3.96%
Profit per employee	$-20,101
Profitable quarters	2
Revenue per employee	$507,071
ROA	1.56%
ROA (5Y)	1.34%
ROCE	2.9%
ROE	-2.98%
ROE (5Y)	-4.7%
ROIC	3.29%
ROIC (5Y)	2.5%
SBC / revenue	1.47%
Tax / revenue	0.66%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	440.54%
EPS growth (QoQ)	-1.72%
EPS growth quarters	1
EPS growth years	0
FCF growth	4.99%
FCF growth (Q)	35.56%
Gross profit growth	13.24%
Gross profit growth (Q)	11.92%
Gross profit growth 3Y	3.92%
Gross profit growth 5Y	2.29%
Net income growth (Q)	390.91%
Net income growth (QoQ)	-5.26%
Net income growth quarters	1
Net income growth years	0
OCF growth	7.87%
OCF growth (Q)	16.88%
OCF growth (QoQ)	2,030.77%
OCF growth 3Y	73.57%
Operating income growth	58.14%
Operating income growth (Q)	38.82%
Operating income growth 3Y	-1.43%
Operating income growth 5Y	12.34%
Revenue growth	11.95%
Revenue growth (Q)	10.23%
Revenue growth (QoQ)	-0.22%
Revenue growth 3Y	5.1%
Revenue growth 5Y	1.99%
Revenue growth quarters	5
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-238M
Depreciation and amortization	$667M
EBIT	$340M
EBITDA	$1B
EPS	$-0.41
FCF per share	$0.76
Financing cash flow	$-310M
Free cash flow	$379M
Free cash flow minus SBC	$305M
Gross profit	$2.8B
Income taxes	$33M
Investing cash flow	$-335M
Net borrowing	$12M
Net cash flow	$-9M
Net income	$-199M
Operating cash flow minus SBC	$543M
Operating income	$340M
Revenue	$5B
Stock-based compensation	$74M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.33
Book value per share	$13.19
Debt / EBITDA	3.92
Debt / equity	0.64
Debt / FCF	11.17
Goodwill	$4.8B
Interest coverage	1.25
Long-term assets	$9.8B
Long-term liabilities	$5.1B
Net cash (debt)	$-3.7B
Net cash / market cap	-32.78%
Net debt / EBITDA	3.68
Net debt / equity	0.56
Net debt / FCF	9.77
Piotroski F-Score	5
Property, plant and equipment	$1.4B
Shareholders' equity	$6.6B
Tangible book value	$-1.5B
Tangible book value per share	$-2.92
Total assets	$13.6B
Total cash	$530M
Total debt	$4.2B
Total liabilities	$7B
WACC	11.3%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.37
Current assets	$3.8B
Current liabilities	$1.9B
Current ratio	2.05
Inventory turnover	1.3
Net working capital	$1.5B
Quick ratio	0.91
Working capital	$1.9B
Working capital turnover	2.41

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.5%
Dividend yield	0%
Shareholder yield	0.5%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$23.52
1D price change	-0.07%
1M price change	1.66%
1M total return	1.66%
1W price change	-0.09%
1W total return	-0.09%
1Y price change	1.84%
1Y return CAGR	1.84%
1Y total return	1.84%
20-day SMA	$22.68
200-day SMA	$23.81
3M price change	-10.74%
3M total return	-10.74%
3Y price change	156.27%
3Y return CAGR	36.84%
3Y total return	156.27%
50-day SMA	$23.16
50-day SMA vs 200-day SMA	50under200
52-week high	$27.98
52-week high date	2026-08-05
52-week low	$19.40
52-week low date	2026-05-19
5Y price change	-31.91%
5Y return CAGR	-7.4%
5Y total return	-31.91%
6M price change	2.67%
6M total return	2.67%
All-time high	$37.61
All-time high date	2018-09-27
All-time low	$7.88
All-time low date	2023-05-31
Average true range (ATR)	$0.70
Average volume	4.7M
Beta (1Y)	0.23
Beta (2Y)	1.01
Beta (5Y)	1.71
Change from 52-week high	-19.1%
Change from 52-week low	16.68%
Change from all-time high	-39.7%
Change from all-time low	187.82%
Change from open	-0.77%
Day's gap	0.71%
Dollar volume	$67.8M
High price	$22.91
Low price	$22.57
Monthly RSI	55.77
Open price	$22.81
Position in 52-week range	19.12%
Premarket change	0.92%
Premarket close	$22.65
Premarket price	$22.86
Premarket volume	26.1K
Previous close	$22.65
Price vs 150-day SMA	-3.57%
Price vs 20-day SMA	0%
Price vs 200-day SMA	-4.73%
Price vs 50-day SMA	-2.07%
Relative volume	0.63
RSI	47.9
Sharpe ratio	0.16
Sharpe ratio (3Y)	0.79
Sharpe ratio (5Y)	-0.04
Sortino ratio	0.36
Sortino ratio (3Y)	1.44
Sortino ratio (5Y)	0.08
Volume	3M
Weekly RSI	47.67
YTD price change	0.22%
YTD total return	0.22%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	495.4M
Float percentage	99.16%
Shares change (QoQ)	-0.02%
Shares change (YoY)	-0.5%
Shares held by insiders	0.71%
Shares held by institutions	114.42%
Shares outstanding	499.6M
Short % of float	7.53%
Short % of shares	7.46%
Short ratio	6.7 days

Deeper analysis on ELAN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ELAN report

Is a complete ELAN research report available?

No complete published report is available for Elanco Animal Health Incorporated (ELAN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Elanco Animal Health Incorporated (ELAN)

Price

Financial snapshot

Fair-value bridge

Latest news · ELAN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ELAN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ELAN

Frequently asked questions